share_log

Illumina | 10-Q: Q3 2024 Earnings Report

Illumina | 10-Q: Q3 2024 Earnings Report

Illumina | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/07 02:29

Moomoo AI 已提取核心訊息

Illumina reported Q3 2024 revenue of $1.08 billion, down 3% year-over-year, while posting net income of $705 million compared to a $754 million loss last year. The profit was largely driven by a $489 million gain from the European Commission withdrawing its previously imposed fine. Core sequencing consumables revenue increased by $46 million, though instrument sales declined 41% to $107 million.Gross margin improved to 68.9% from 61.1% in Q3 2023, benefiting from operational excellence initiatives, favorable product mix, and lower warranty costs. The company completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. Operating expenses decreased significantly to $4 million from $1.44 billion last year, primarily due to the absence of prior year's goodwill impairment charges.The company ended the quarter with $869 million in cash and issued $500 million in new term notes due 2026. The Board authorized a new $1.5 billion share repurchase program, with $1.4 billion remaining available. For the full year, management continues to focus on cost reduction initiatives while maintaining investment in high-growth areas despite ongoing macroeconomic uncertainties.
Illumina reported Q3 2024 revenue of $1.08 billion, down 3% year-over-year, while posting net income of $705 million compared to a $754 million loss last year. The profit was largely driven by a $489 million gain from the European Commission withdrawing its previously imposed fine. Core sequencing consumables revenue increased by $46 million, though instrument sales declined 41% to $107 million.Gross margin improved to 68.9% from 61.1% in Q3 2023, benefiting from operational excellence initiatives, favorable product mix, and lower warranty costs. The company completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. Operating expenses decreased significantly to $4 million from $1.44 billion last year, primarily due to the absence of prior year's goodwill impairment charges.The company ended the quarter with $869 million in cash and issued $500 million in new term notes due 2026. The Board authorized a new $1.5 billion share repurchase program, with $1.4 billion remaining available. For the full year, management continues to focus on cost reduction initiatives while maintaining investment in high-growth areas despite ongoing macroeconomic uncertainties.
Illumina報告2024年第三季度營業收入爲10.8億元，同比下降3%，同時凈利潤爲70500萬元，而去年則爲75400萬元的虧損。利潤主要受益於歐洲委員會撤回之前實施的罰款，獲得48900萬元的收益。核心測序耗材營業收入增加了4600萬元，儘管儀器銷售下降了41%，至10700萬元。毛利率從2023年第三季度的61.1%提高至68.9%，受益於運營卓越的舉措、良好的產品組合和較低的保修成本。該公司於2024年6月完成了GRAIL的剝離，保留了14.5%的股份。營業費用大幅下降至400萬元，去年爲14.4億元，主要是由於去年沒有了商譽減值費用。公司在季度末手頭現金爲86900萬元，併發行了50000萬元的新定期票據，到期於2026年。董事會批准了一項新的15億元股票回購計劃，仍有14億元可用。爲整年，管理層繼續專注於成本降低舉措，同時在高增長領域保持投資，儘管面臨持續的宏觀經濟不確定性。
Illumina報告2024年第三季度營業收入爲10.8億元，同比下降3%，同時凈利潤爲70500萬元，而去年則爲75400萬元的虧損。利潤主要受益於歐洲委員會撤回之前實施的罰款，獲得48900萬元的收益。核心測序耗材營業收入增加了4600萬元，儘管儀器銷售下降了41%，至10700萬元。毛利率從2023年第三季度的61.1%提高至68.9%，受益於運營卓越的舉措、良好的產品組合和較低的保修成本。該公司於2024年6月完成了GRAIL的剝離，保留了14.5%的股份。營業費用大幅下降至400萬元，去年爲14.4億元，主要是由於去年沒有了商譽減值費用。公司在季度末手頭現金爲86900萬元，併發行了50000萬元的新定期票據，到期於2026年。董事會批准了一項新的15億元股票回購計劃，仍有14億元可用。爲整年，管理層繼續專注於成本降低舉措，同時在高增長領域保持投資，儘管面臨持續的宏觀經濟不確定性。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Exagen
    XGN
    -- 3.990
    Atlantic International
    ATLN
    -- 5.650
    Neuronetics
    STIM
    -- 2.460
    XWELL Inc
    XWEL
    -- 1.2500
    Precipio
    PRPO
    -- 6.5100

    解鎖榜首股票

    熱門討論
    特朗普2.0時代倒計時！全球股市的下一個風口？
    🎙️️討論： 1. 加密貨幣政策能否利好crypto? 2. 關稅政策能否利好中概等海外資產？ 展开
    特朗普2.0機會預告：在總統上任之前猜測市場贏家！